Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Cancer

Understanding resistance to antiangiogenic agents

Nature Reviews Drug Discovery volume 13, page 726 (2014)Cite this article

Subjects

Access through your institution
Buy or subscribe

The molecular mechanisms by which tumours acquire resistance to antiangiogenic therapies — such as small-molecule receptor tyrosine kinase inhibitors (RTKIs) — remain poorly understood. Here, applying global transcriptomic, proteomic and metabolomic approaches to preclinical cancer models, the authors provide mechanistic insights into how tumours adapt their metabolism to antiangiogenic therapy. Following RTKI treatment withdrawal, tumours undergo a metabolic shift from a glycolytic phenotype towards lipid metabolism and increased TCA activity, which is associated with rapid tumour regrowth and accelerated metastatic dissemination. Inhibition of fatty acid synthase reversed this malignant adaptation and prevented tumour relapse, which may have clinical implications.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Sounni, N. E. et al. Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal. Cell Metabol. 20, 280–294 (2014)

    Article  CAS  Google Scholar 

Download references

Authors
  1. Sarah Crunkhorn
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Crunkhorn, S. Understanding resistance to antiangiogenic agents. Nat Rev Drug Discov 13, 726 (2014). https://doi.org/10.1038/nrd4450

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrd4450

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research